Incivek, Incivo(telaprevir)
Incivek, Incivo (telaprevir) is a protein pharmaceutical. Telaprevir was first approved as Incivek on 2011-05-23. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. It is known to target lysosomal protective protein and chymotrypsin-like elastase family member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Telaprevir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INCIVEK | Vertex Pharmaceuticals | N-201917 DISCN | 2011-05-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis c | — | D006526 | B19.2 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 11 | 15 | 10 | 1 | 1 | 36 |
| Hepatitis | D006505 | — | K75.9 | 7 | 15 | 10 | 1 | — | 31 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 4 | 14 | 8 | 1 | — | 25 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 6 | 5 | 1 | — | 15 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis | D006521 | — | K73.9 | 1 | 3 | 2 | — | — | 6 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | — | — | 3 |
| Virus diseases | D014777 | — | B34 | — | 1 | 1 | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Telaprevir |
| INN | telaprevir |
| Description | Telaprevir is an oligopeptide consisting of N-(pyrazin-2-ylcarbonyl)cyclohexylalanyl, 3-methylvalyl, octahydrocyclopenta[c]pyrrole-1-carboxy, and 3-amino-N-cyclopropyl-2-oxohexanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. It has a role as a peptidomimetic, a hepatitis C protease inhibitor and an antiviral drug. It is an oligopeptide, a member of pyrazines, a cyclopentapyrrole and a member of cyclopropanes. |
| Classification | Protein |
| Drug class | antivirals: serine protease inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 |
Identifiers
| PDB | — |
| CAS-ID | 402957-28-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL231813 |
| ChEBI ID | 68595 |
| PubChem CID | 3010818 |
| DrugBank | DB05521 |
| UNII ID | 655M5O3W0U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CTSA
CTSA
CELA1
CELA1
Organism
Homo sapiens
Gene name
CTSA
Gene synonyms
PPGB
NCBI Gene ID
Protein name
lysosomal protective protein
Protein synonyms
beta-galactosidase 2, beta-galactosidase protective protein, Carboxypeptidase C, Carboxypeptidase L, carboxypeptidase Y-like kininase, carboxypeptidase-L, Cathepsin A, deamidase, lysosomal carboxypeptidase A, PPCA, Protective protein cathepsin A, Protective protein for beta-galactosidase, urinary kininase
Uniprot ID
Mouse ortholog
Ctsa (19025)
lysosomal protective protein (Q8VEF6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Incivek – Vertex Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Telaprevir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,597 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37,106 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use